2006 Vol. 8, No. 7 1295–1297

Formal Total Synthesis of (—)-Emetine Using Catalytic Asymmetric Allylation of Cyclic Imines as a Key Step

Takashi Itoh,* Michiko Miyazaki, Hiromi Fukuoka, Kazuhiro Nagata, and Akio Ohsawa

School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan itoh-t@pharm.showa-u.ac.jp

Received December 14, 2005

ABSTRACT

Catalytic asymmetric allylation of 3,4-dihydro-6,7-dimethoxyisoquinoline was carried out using allyltrimethoxysilane in the presence of Cu(I) and tol-BINAP. The allyl adduct thus obtained was transformed to a chiral synthetic intermediate for (–)-emetine in good yield. The procedure was applied to the total synthesis of *ent*-emetine.

Isoquinoline alkaloids¹ have long attracted much attention due to their biological activities, which involve recent discoveries for α-glucosidase² and Parkinson's disease.³ Most of these compounds have a common characteristic in their structures; that is, they have a chiral center at the C-1 position of the isoquinoline nucleus. Thus, the formation of the chiral center is a crucial step for general synthetic methods of isoquinoline alkaloids.

There are, however, only a few methods^{4–6} for constructing a chiral 1-substituted tetrahydroisoquinoline nucleus in high stereoselectivity.

In the course of our research for the asymmetric synthesis of isoquinoline alkaloids, we have found that *N*-acylisoquinolinium salts with a chiral center in the acyl group

underwent diastereoselective addition with allyltributyltin and silyl enol ethers to give 1-substituted tetrahydroisoquinoline derivatives in a stereoselective manner.⁷ These results prompted us to investigate a catalytic process for the reaction, and it was found that 3,4-dihydro-6,7-dimethoxyisoquinoline (1) was a substrate for the addition of allyltrimethoxysilane in the presence of a catalytic amount of Cu(I) salt and a chiral phosphine ligand to give 1-allyl-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline (2) in good yield and moderate stereoselectivity. The enantiomeric excess was further increased by recrystallization in the presence of dibenzoyl tartaric acid to afford a pure enantiomer. The allyl adduct thus obtained was transformed to a key intermediate for the total synthesis of (—)-emetine in short steps, and the *ent-*

^{(1) (}a) Rozwadowska, M. D. Heterocycles **1994**, *39*, 903. (b) Chrzanowska, M.; Rozwadowska, M. D. Chem. Rev. **2004**, *104*, 3341.

⁽²⁾ Takada, K.; Uehara, T.; Nakao, Y.; Matsunaga, S.; van Soest, R. W. M.; Fusetani, N. *J. Am. Chem. Soc.* **2004**, *126*, 187.

^{(3) (}a) Nagatsu, T. Neurosci. Res. 1997, 29, 99. (b) Sano, T. J. Synth. Org. Chem. Jpn. 1999, 57, 136. (c) Yamakawa, T.; Ohta, S. Biochem. Biophys. Res. Commun. 1997, 236, 676. (d) Thull, U.; Kneubuler, S.; Gaillard, P.; Carrupt, P. A.; Testa, B.; Altomare, C.; Carotti, A.; Jenner, P.; McNaught, K. St. P. Biochem. Pharmacol. 1995, 50, 869.

⁽⁴⁾ Meyers, A. I.; Dickman, D. A.; Boes, M. *Tetrahedron* **1987**, *43*, 5095 and references therein.

^{(5) (}a) Uematsu, N.; Fujii, A.; Hashiguchi, S.; Ikariya, T.; Noyori, R. *J. Am. Chem. Soc.* **1996**, *118*, 4916. (b) Noyori, R.; Hashiguchi, S. *Acc. Chem. Res.* **1997**, *30*, 97.

^{(6) (}a) Taylor, M. S.; Jacobsen, E. N. J. Am. Chem. Soc. **2004**, 126, 10558. (b) Tayler, M. S.; Tokunaga, N.; Jacobsen, E. N. Angew. Chem., Int. Ed. **2005**, 44, 2

⁽⁷⁾ Itoh, T.; Nagata, K.; Miyazaki, M.; Kameoka, K.; Ohsawa, A. *Tetrahedron* **2001**, *57*, 8827 and references therein.

emetine was synthesized by the same method. This paper describes these results.

Although there are a few papers on the catalytic asymmetric allylation of imines,⁸ there has been no report concerning the catalytic allylation of cyclic imines.⁹ Although Yamamoto et al. recently reported a general method for the allylation of various kinds of imines, they showed the incompatibility of cyclic imines to their reaction system.^{8d} Recently, a new allylation reaction of ketones and aldehydes has been published by Shibasaki et al.¹⁰ using allyltrimethoxysilane and a catalytic amount of Cu(I) salt. We applied their reaction system to the allylation of 6,7-dimethoxy-3,4-dihydroisoquinoline and found that the reaction proceeded in a stereoselective manner as shown in Table 1.

Table 1

entry	solvent	chiral ligand	time	yield of 2 (%)	ee of 2 ¹² (%)
1	THF		20 h	72	
2	THF	(R)-tol-BINAP	1 d	91	71(S)
3	THF	(R)-BINAP	1 d	35	71(S)
4	THF	(R,R)-DIPAMP	1 d	78	5
5	THF	(R,R)-CHIRAPHOS	1 d	31	21(S)
6	DMF	(R)-tol-BINAP	1 d	21	50(S)
7	ether	(R)-tol-BINAP	1 d	37	47(S)
8	dioxane	(R)-tol-BINAP	1 d	35	67 (S)

Various phosphine derivatives were investigated as chiral ligands, and it was found that tol-BINAP in THF at room temperature afforded the best result for the present reaction. The yield of $\bf 2$ was lowered to 21% by the reaction at 10 °C without an increase of the ee, and the reaction did not proceed at 0 °C. Other allylation reagents such as allyltributyltin afforded a racemic product. Although the stereoselectivity is moderate, this is the first example that a cyclic imine is adopted as a catalytic allylation reaction.

The product 2 thus obtained was treated with (-)-dibenzoyl-L-tartaric acid to form a mixture of the diastereomeric salts, which was recrystallized from acetonitrile/H₂O (20:1) to give optically pure 2 (97% ee) in 67% yield based on the starting material.¹¹

(10) Yamasaki, S.; Fujii, K.; Wada, R.; Kanai, M.; Shibasaki, M. *J. Am Chem. Soc.* **2002**, *124*, 6536.

With a practical amount of compound 2 in hand, we decided to functionalize the obtained allyl group. After the protection of an amino group of 2, reaction of 3 with various monosubstituted alkenes using the second-generation Grubbs' catalyst was carried out, and it was found that the crossmetathesis products were obtained in high yields and good stereoselectivity. Without the Boc protecting group, the metathesis reaction did not proceed.

By using the ethyl acrylate, sufficient stereoselectivity was obtained to give an adequate amount of a functionalized (*E*)-alkene derivative **4** (Scheme 1).

The deprotection of **4** followed by Michael addition of **5** with methyl vinyl ketone afforded an *N*-(3-oxobutyl) derivative, which was then cyclized to **6** in a completely diastereoselective manner (Scheme 2). In our first plan, the acetyl group would be transformed to the corresponding ethyl group according to the reported method, ¹⁴ but our attempt to reduce the keto group to give **7** resulted in a very low yield under various conditions. ¹⁵

Thus, we changed the synthetic procedure as follows (Scheme 3). Although Michael addition of acrolein to compound 5 resulted in a complex mixture of the products, slowing the addition of acrolein considerably improved the reaction yield to a practical level. That is, the addition of acrolein to 5 over 5 h followed by treatment with pyrrolidine afforded a ring-closing product 8 in good yield and complete stereoselectivity. Although the compound 8 was obtained at first as its epimer at the C-3 position (according to emetine numbering), the epimeric compound rapidly isomerized to 8 under the reaction conditions. The formyl derivative 8 thus

1296 Org. Lett., Vol. 8, No. 7, 2006

^{(8) (}a) Nakamura, H.; Nakamura, K.; Yamamoto, Y.J. Am. Chem. Soc. 1998, 120, 4242. (b) Fang, X.; Johannsen, M.; Yao, S.; Gathergood, N.; Hazell, R. G.; Jorgensen, K. A. J. Org. Chem. 1999, 64, 4844. (c) Gastner, T.; Ishitani, H.; Akiyama, R.; Kobayashi, S. Angew. Chem., Int. Ed. 2001, 40, 1896. (d) Fernandes, R. A.; Stimac, A.; Yamamoto, Y. J. Am. Chem. Soc. 2003, 125, 14133.

⁽⁹⁾ There are a few reports which claimed the asymmetric allylation using a stoichiometrical amount of chiral compound; see: Nakamura, M.; Hirai, A.; Nakamura, E. *J. Am. Chem. Soc.* **1996**, *118*, 8489 and references therein. (10) Yamasaki, S.; Fujii, K.; Wada, R.; Kanai, M.; Shibasaki, M. *J. Am*.

⁽¹¹⁾ With three times of careful recrystallization, the tartrate salt of racemic 2 afforded the enantiomeric 2 in 97% ee.

⁽¹²⁾ The absolute configuration of the compound 2 was determined by the transformation to the known compound 10.

⁽¹³⁾ Nagata, K.; Itoh, T.; Fukuoka, H.; Nakamura, S.; Ohsawa, A. Heterocycles 2005, 65, 1283.

⁽¹⁴⁾ Hirai, Y.; Terada, T.; Hasegawa, A.; Yamazaki, T. Chem. Pharm. Bull. 1998, 36, 1343.

⁽¹⁵⁾ Other than the reported method that used ethanedithiol—TFA followed by Raney Ni, several reduction systems were tested which involve various variants of Wolff—Kishner or Clemmensen reduction, but the product **7** was not obtained in more than 7% yield.

obtained underwent the Wittig reaction with methyltriphenylphosphonium bromide followed by treatment with methanol to give alkene 9. A catalytic hydrogenation of 9 resulted in the formation of compound 10, which was reported by Tietze¹⁶ as an intermediate for the synthesis of (–)-emetine. Thus, the stereoselectivity of the present reaction was proved to be consistent with that of the natural product.

In our synthesis, the overall yield of **10** was 21.5% in 8 steps from the starting material **1**. Since the reported synthesis¹⁶ afforded **10** in 3.2% yield via 12 steps, the present

method gives a better way of obtaining the important intermediate **10**, which can also be transformed to several alkaloids such as psychotrine¹⁷ and tubulosine.¹⁸

The final stage of the total synthesis of (-)-emetine (11) was accomplished according to Tietze's method¹⁶ in three steps (Scheme 4).

Using the present procedure, we obtained *ent*-emetine ((+)-emetine) in overall yield of 8.5% from 1and (S)-tol-BINAP.

In this paper, we have described asymmetric formal total synthesis of (-)-emetine and the synthesis of (+)-emetine in a completely stereoselective manner. In the key step, catalytic allylation was carried out to introduce an allyl group at the C-1 position of the isoquinoline nucleus using tol-BINAP as a chiral source. The application of the allyl adduct 2 to the total synthesis of other isoquinoline alkaloids and the biological activity of *ent*-emetine are now under investigation.

Supporting Information Available: Detailed experimental procedures and spectral data for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL0530326

Org. Lett., Vol. 8, No. 7, 2006

⁽¹⁶⁾ Tietze, L. F.; Rackelmann, N.; Sekar, G. Angew. Chem., Int. Ed. 2003, 42, 4254.

^{(17) (}a) Battersby, A. R.; Turner, J. C. J. Chem. Soc. 1960, 717. (b) Teitel, S.; Brossi, A. J. Am. Chem. Soc. 1966, 88, 4068. (c) Fujii, T.; Ohba, M.; Yonemitsu, O.; Ban, Y. Chem. Phar. Bull. 1982, 30, 598. (d) Fujii, T.; Yamada, K.; Minami, S.; Yoshifuji, S.; Ohba, M. Chem. Pharm. Bull. 1983, 31, 2583. (e) Fujii, T.; Ohba, M. Chem. Pharm. Bull. 1985, 33, 144. (f) Fujii, T.; Ohba, M. Chem. Pharm. Bull. 1985, 33, 583.

^{(18) (}a) Brauchli, P.; Deulofeu, V.; Budzikiewicz, H.; Djerassi, C. J. Am. Chem. Soc. 1964, 86, 1895. (b) Openshaw, H. T.; Robson, N. C.; Whittaker, N. J. Chem. Soc. 1969, 101. (c) Kametani, T.; Suzuki, Y.; Ihara, M. Can. J. Chem. 1979, 57, 1679. (d) Ihara, M.; Yasui, K.; Taniguchi, N.; Fukumoto, K. J. Chem. Soc. 1990, 1469. (e) Tietze, L. F.; Rackelmann, N.; Muller, I. Chem. Eur. J. 2004, 10, 2722.